Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Glucagon-like peptide 1 (GLP-1) as a regulator of food intake and body weight: therapeutic perspectives
Cardiovascular outcome studies Although multiple clinical trials evaluating cardiovascular events associated with GLP-1 RA use as the primary outcome are currently ongoing (Table 1), abundant non-primary outcome data are available from many clinical trials on the efficacy of GLP-1 RAs marketed earlier, such as exenatide (DURATION studies) and liraglutide (LEAD studies)
-
Etiology of lipid-laden macrophages in the lung
An oral option for patients with T2D with efficacy in ASCVD risk reduction regardless of existing ASCVD is preferable to those who are needle phobic and may relieve concerns from prescribers about injection administration, especially in patients with dexterity issues or other neurologic conditions that may limit mobility
US$ 26.32
US$ 21.93
US$ 28.69
US$ 21.74
US$ 22.84
US$ 26.86
US$ 23.03
US$ 23.17
